Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy

Carole Fleury,Anne Quinquenel,Luc-Matthieu Fornecker,Loic Ysebaert,Catherine Thieblemont,Jean-Marc Zini,Pierre Feugier,Lise Willems,Jean-François Collon,Virginie Eclache,Gregory Lazarian,Remi Letestu,Florence Cymbalista,Fanny Baran-Marszak

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2018）

Cited 0|Views33
No score
Abstract
Targeted therapies such as the BTK inhibitor Ibrutinib profoundly changed the management of patients with CLL. Molecular mechanisms underlying disease progression on therapy are being actively explored, and mutations in BTK or PLCγ2 gene have been identified as an important one.
More
Translated text
Key words
chronic lymphocytic leukemia,ibrutinib,mutations,resistance
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined